• Industry
  • Finance
  • Culture
  • Politics
  • Science
  • Wellness
  • Industry
  • Finance
  • Culture
  • Politics
  • Science
  • Wellness
AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy
Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy
Two New Studies Are Rewriting the Rules of Psychedelic Drug Development
Starting 2026: Why Neuroplastogens Are Quietly Redefining the Psychedelic Medicine Narrative
Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward
Delix Therapeutics Reports Strong Phase Ib Results
Childhood Trauma’s Role in Men’s Substance Use Disorders
Human-Centered AI in Healthcare
Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up
The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch
Shop

Wonderland Day One: A huge success

Microdose by Microdose
November 9, 2021
in Industry
Reading Time: 2 mins read
A A
Wonderland Day One: A huge success

We’ve been working on it for what seems like forever — and day one of Wonderland was a huge success.

World class researchers, heavyweight celebrities like Mike Tyson, and countless entrepreneurs, advocates and investors. The psychedelic medicine industry has officially arrived.

 

Running from November 8-9, 2021 in Miami, Florida at the Adrienne Arsht Center for the Performing Arts, Wonderland is an impressive collection of global psychedelic medicine leaders, from scientists and researchers, investors and entrepreneurs, therapists and patients, government officials, and media, all championing the growth of the psychedelic medicine industry.

[bsa_pro_ad_space id=2]
ADVERTISEMENT

 

Continue on your trip...

Two New Studies Are Rewriting the Rules of Psychedelic Drug Development

Starting 2026: Why Neuroplastogens Are Quietly Redefining the Psychedelic Medicine Narrative

Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward

Wonderland day one highlights included:

  • Cybin hosting a press conference announcing impressive R&D results of their new drug candidate CYB-003
  • Daniel Carcillo, former professional hockey player and CEO of Wesana Health, sat down for a fireside chat with boxing great Mike Tyson for an inspirational talk about the life-changing effects of psychedelics

 

Low Cost Lasix For Sale
  • Robin Carhart-Harris, Distinguished Professor of Neurology & Psychiatry, Director Psychedelics Division, Neuroscape, UCSF
  • Rick Doblin from MAPS in conversation with Microdose CEO Patrick Moher
  • Panels included The Pathway to Federal Acceptance, Precision Medicine and Psychedelics, Next-Generation Psychedelics, and many others

 

The Adrienne Arsht Center was filled with innovative exhibitors, industry-leading sponsors, and entrepreneurs and investors meeting in-person and blazing new paths for the entire industry.

Wonderland day two will continue with:

  • Dr. Matthew W. Johnson, Ph.D., Professor of Psychiatry and Behavioral Sciences at Johns Hopkins
  • Wonderful panels including: Evolution of Ibogaine Treatment, Psilocybin for Smoking Cessation, Investing the Shamanic Way, Patent Wars, Finance and Psychedelics

 

[bsa_pro_ad_space id=2]
ADVERTISEMENT
Microdose

Microdose

At our core, we champion integrity, diversity, and objectivity, providing trusted content that unites a wide array of experts and fosters unbiased opinions, ultimately empowering the psychedelic medicine community to flourish and make a positive impact on the world.

Next Post
First legal Psilocybin Mushroom group therapy treatment for nine end-of life-patients

First legal Psilocybin Mushroom group therapy treatment for nine end-of life-patients

Please login to join discussion

Who do you think will be first to successfully develop a psychedelic drug?
This field is for validation purposes and should be left unchanged.

Latest News

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

Two New Studies Are Rewriting the Rules of Psychedelic Drug Development

ADVERTISEMENT

Follow us on social

Microdose is your guide to psychedelics. Our mission is to shift the world’s perception of psychedelic medicine.

Read the News
  • Industry
  • Culture
  • Science
  • Finance
  • Law & Politics
  • Health & Wellness
  • Industry
  • Culture
  • Science
  • Finance
  • Law & Politics
  • Health & Wellness
Online Courses
  • Microdosing
  • MDMA
  • Ketamine
  • Psychedelic Counseling
  • Addiction Treatment
  • Classic Psychedelics
  • Microdosing
  • MDMA
  • Ketamine
  • Psychedelic Counseling
  • Addiction Treatment
  • Classic Psychedelics
Subscribe for Exclusive Updates

Terms & Conditions / Privacy Policy

© 2026 MD Media Inc. All rights reserved. The information provided on this website does not, and is not intended to, constitute financial, legal or medical advice. All information, content, and materials available on this site are for general educational and informational purposes only.

WordPress Ads
No Result
View All Result
  • Landing Page
  • Buy JNews
  • Support Forum
  • Contact Us

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.